$VCEL
Vericel Corp Stock $vcel

$vcel Overview Financials Valuation SEC Filings Company Website

2015 Q2 Form 10-Q Financial Statement

#000162828015004203 Filed on May 14, 2015

Income Statement

Concept	2015 Q2	2015 Q1	2014 Q1
Revenue	$13.59M	$10.85M	$0.00
YoY Change	206.63%		-100.0%
Cost Of Revenue	$6.901M	$5.568M	$0.00
YoY Change	37.77%		-100.0%
Gross Profit	$6.689M	$5.281M	$0.00
YoY Change	-1259.27%		-100.0%
Gross Profit Margin	49.22%	48.68%
Selling, General & Admin	$5.585M	$5.476M	$1.374M
YoY Change	55.96%	298.54%	-15.86%
% of Gross Profit	83.5%	103.69%
Research & Development	$3.369M	$4.377M	$3.271M
YoY Change	-22.8%	33.81%	-40.94%
% of Gross Profit	50.37%	82.88%
Depreciation & Amortization	$200.0K	$328.0K	$97.00K
YoY Change	100.0%	238.14%	-35.33%
% of Gross Profit	2.99%	6.21%
Operating Expenses	$8.954M	$9.853M	$4.645M
YoY Change	12.7%	112.12%	-35.23%
Operating Profit	-$2.265M	-$4.572M	-$4.645M
YoY Change	-73.42%	-1.57%	-35.17%
Interest Expense	$2.000K	$2.000K	$2.000K
YoY Change	0.0%	0.0%	-33.33%
% of Operating Profit
Other Income/Expense, Net	$113.0K	-$290.0K	-$1.350M
YoY Change	-97.09%	-78.52%	-183.28%
Pretax Income	-$2.150M	-$4.860M	-$6.000M
YoY Change	-53.66%	-19.0%	8.3%
Income Tax
% Of Pretax Income
Net Earnings	-$2.152M	-$4.862M	-$5.995M
YoY Change	-53.6%	-18.9%	8.13%
Net Earnings / Revenue	-15.84%	-44.82%
Basic Earnings Per Share
Diluted Earnings Per Share	-$90.37K	-$204.3K	-$1.022M
COMMON SHARES
Basic Shares Outstanding	23.79M shares		6.158M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2015 Q2	2015 Q1	2014 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$20.20M	$25.90M	$8.800M
YoY Change	176.71%	194.32%	-4.35%
Cash & Equivalents	$20.20M	$25.90M	$8.800M
Short-Term Investments
Other Short-Term Assets	$2.270M	$845.0K	$400.0K
YoY Change	272.13%	111.25%	33.33%
Inventory	$2.078M	$2.005M
Prepaid Expenses
Receivables	$8.980M	$9.166M
Other Receivables	$0.00	$0.00
Total Short-Term Assets	$33.55M	$37.92M	$9.236M
YoY Change	137.71%	310.56%	-3.04%
LONG-TERM ASSETS
Property, Plant & Equipment	$4.616M	$3.446M	$642.0K
YoY Change	93.38%	436.76%	-39.2%
Goodwill
YoY Change
Intangibles	$3.057M	$3.127M
YoY Change	-8.39%
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets	$7.673M	$6.573M	$642.0K
YoY Change	34.05%	923.83%	-39.2%
TOTAL ASSETS
Total Short-Term Assets	$33.55M	$37.92M	$9.236M
Total Long-Term Assets	$7.673M	$6.573M	$642.0K
Total Assets	$41.22M	$44.49M	$9.878M
YoY Change	107.8%	350.42%	-6.65%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$6.120M	$6.726M	$2.500M
YoY Change	110.38%	169.04%	-16.67%
Accrued Expenses	$140.0K	$154.0K	$400.0K
YoY Change	-94.41%	-61.5%	-55.56%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change	-100.0%
Long-Term Debt Due			$2.000K
YoY Change
Total Short-Term Liabilities	$10.82M	$12.62M	$6.109M
YoY Change	-36.56%	106.65%	42.87%
LONG-TERM LIABILITIES
Long-Term Debt	$91.00K	$100.0K	$0.00
YoY Change			-100.0%
Other Long-Term Liabilities	$66.00K	$66.00K
YoY Change
Total Long-Term Liabilities	$157.0K	$166.0K	$0.00
YoY Change			-100.0%
TOTAL LIABILITIES
Total Short-Term Liabilities	$10.82M	$12.62M	$6.109M
Total Long-Term Liabilities	$157.0K	$166.0K	$0.00
Total Liabilities	$10.98M	$12.79M	$6.100M
YoY Change	-35.82%	109.67%	42.59%
SHAREHOLDERS EQUITY
Retained Earnings			-$293.8M
YoY Change			4.13%
Common Stock	$306.6M	$305.9M	$259.1M
YoY Change		18.06%	5.53%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$30.24M	$31.70M	$3.769M
YoY Change
Total Liabilities & Shareholders Equity	$41.22M	$44.49M	$9.878M
YoY Change	107.8%	350.42%	-6.81%

Cashflow Statement

Concept	2015 Q2	2015 Q1	2014 Q1
OPERATING ACTIVITIES
Net Income	-$2.152M	-$4.862M	-$5.995M
YoY Change	-53.6%	-18.9%	8.13%
Depreciation, Depletion And Amortization	$200.0K	$328.0K	$97.00K
YoY Change	100.0%	238.14%	-35.33%
Cash From Operating Activities	-$4.480M	-$4.110M	-$4.670M
YoY Change	-26.19%	-11.99%	-30.92%
INVESTING ACTIVITIES
Capital Expenditures	-$1.210M	-$350.0K	$0.00
YoY Change	12000.0%		-100.0%
Acquisitions		$353.0K	$0.00
YoY Change
Other Investing Activities	$0.00	-$35.00K	$0.00
YoY Change	-100.0%
Cash From Investing Activities	-$1.200M	-$320.0K	$0.00
YoY Change	-215.38%		-100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			$5.286M
YoY Change
Debt Paid & Issued, Net			$4.000K
YoY Change			-63.64%
Cash From Financing Activities	0.000	-10.00K	5.450M
YoY Change	-100.0%	-100.18%	129.96%
NET CHANGE
Cash From Operating Activities	-4.480M	-4.110M	-4.670M
Cash From Investing Activities	-1.200M	-320.0K	0.000
Cash From Financing Activities	0.000	-10.00K	5.450M
Net Change In Cash	-5.680M	-4.440M	780.0K
YoY Change	261.78%	-669.23%	-117.69%
FREE CASH FLOW
Cash From Operating Activities	-$4.480M	-$4.110M	-$4.670M
Capital Expenditures	-$1.210M	-$350.0K	$0.00
Free Cash Flow	-$3.270M	-$3.760M	-$4.670M
YoY Change	-46.04%	-19.49%	-31.1%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2015Q1	astm	Class Of Warrant Or Right Warrants Exercised Value ClassOfWarrantOrRightWarrantsExercisedValue	0	USD
CY2015Q1	astm	Common Stock Remaining Capacity CommonStockRemainingCapacity	7800000	USD
CY2015Q1	astm	Convertible Preferred Stock Conversion Period ConvertiblePreferredStockConversionPeriod	P5Y
CY2015Q1	astm	Operating And Capital Leases Future Minimum Payments Due OperatingAndCapitalLeasesFutureMinimumPaymentsDue	8911000	USD
CY2015Q1	astm	Operating And Capital Leases Future Minimum Payments Due Current OperatingAndCapitalLeasesFutureMinimumPaymentsDueCurrent	3143000	USD
CY2015Q1	astm	Operating And Capital Leases Future Minimum Payments Due In Four Years OperatingAndCapitalLeasesFutureMinimumPaymentsDueInFourYears	285000	USD
CY2015Q1	astm	Operating And Capital Leases Future Minimum Payments Due In Three Years OperatingAndCapitalLeasesFutureMinimumPaymentsDueInThreeYears	1393000	USD
CY2015Q1	astm	Operating And Capital Leases Future Minimum Payments Due In Two Years OperatingAndCapitalLeasesFutureMinimumPaymentsDueInTwoYears	4090000	USD
CY2015Q1	astm	Operating And Capital Leases Future Minimum Payments Due Thereafter OperatingAndCapitalLeasesFutureMinimumPaymentsDueThereafter	0	USD
CY2015Q1	dei	Amendment Flag AmendmentFlag	false
CY2015Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2015Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2015Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2015
CY2015Q1	dei	Document Period End Date DocumentPeriodEndDate	2015-03-31
CY2015Q1	dei	Document Type DocumentType	10-Q
CY2015Q1	dei	Entity Central Index Key EntityCentralIndexKey	0000887359
CY2015Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	23785653	shares
CY2015Q1	dei	Entity Filer Category EntityFilerCategory	Smaller Reporting Company
CY2015Q1	dei	Entity Registrant Name EntityRegistrantName	Vericel Corp
CY2014Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	4714000	USD
CY2015Q1	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	4320000	USD
CY2014Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	5824000	USD
CY2015Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	6726000	USD
CY2014Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	8191000	USD
CY2015Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	9166000	USD
CY2014Q4	us-gaap	Accrued Bonuses Current And Noncurrent AccruedBonusesCurrentAndNoncurrent	2044000	USD
CY2015Q1	us-gaap	Accrued Bonuses Current And Noncurrent AccruedBonusesCurrentAndNoncurrent	2585000	USD
CY2014Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	605000	USD
CY2015Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	154000	USD
CY2014Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	4397000	USD
CY2015Q1	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	4584000	USD
CY2014Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-71000	USD
CY2015Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-71000	USD
CY2014Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	40000	USD
CY2015Q1	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	86000	USD
CY2015Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	100000	USD
CY2014Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	2500000	shares
CY2015Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	4200000	shares
CY2014Q4	us-gaap	Asset Retirement Obligation Current AssetRetirementObligationCurrent	348000	USD
CY2015Q1	us-gaap	Asset Retirement Obligation Current AssetRetirementObligationCurrent	309000	USD
CY2014Q4	us-gaap	Assets Assets	47579000	USD
CY2015Q1	us-gaap	Assets Assets	44492000	USD
CY2014Q4	us-gaap	Assets Current AssetsCurrent	41490000	USD
CY2015Q1	us-gaap	Assets Current AssetsCurrent	37919000	USD
CY2014Q2	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Intangibles BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles	3400000	USD
CY2015Q1	us-gaap	Capital Leases Future Minimum Payments Due CapitalLeasesFutureMinimumPaymentsDue	150000	USD
CY2015Q1	us-gaap	Capital Leases Future Minimum Payments Due In Four Years CapitalLeasesFutureMinimumPaymentsDueInFourYears	32000	USD
CY2015Q1	us-gaap	Capital Leases Future Minimum Payments Due In Three Years CapitalLeasesFutureMinimumPaymentsDueInThreeYears	43000	USD
CY2015Q1	us-gaap	Capital Leases Future Minimum Payments Due In Two Years CapitalLeasesFutureMinimumPaymentsDueInTwoYears	43000	USD
CY2015Q1	us-gaap	Capital Leases Future Minimum Payments Due Thereafter CapitalLeasesFutureMinimumPaymentsDueThereafter	0	USD
CY2015Q1	us-gaap	Capital Leases Future Minimum Payments Remainder Of Fiscal Year CapitalLeasesFutureMinimumPaymentsRemainderOfFiscalYear	32000	USD
CY2013Q4	us-gaap	Cash Cash	8059000	USD
CY2014Q1	us-gaap	Cash Cash	8836000	USD
CY2014Q4	us-gaap	Cash Cash	30343000	USD
CY2015Q1	us-gaap	Cash Cash	25903000	USD
CY2014Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2015Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2014Q4	us-gaap	Common Stock No Par Value CommonStockNoParValue	0
CY2015Q1	us-gaap	Common Stock No Par Value CommonStockNoParValue	0
CY2014Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	75000000	shares
CY2015Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	75000000	shares
CY2014Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	23786000	shares
CY2015Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	23786000	shares
CY2014Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	23786000	shares
CY2015Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	23786000	shares
CY2014Q4	us-gaap	Common Stock Value CommonStockValue	305008000	USD
CY2015Q1	us-gaap	Common Stock Value CommonStockValue	305931000	USD
CY2014Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-5995000	USD
CY2015Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-4933000	USD
CY2014Q1	us-gaap	Cost Of Goods Sold CostOfGoodsSold	0	USD
CY2015Q1	us-gaap	Cost Of Goods Sold CostOfGoodsSold	5568000	USD
CY2014Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	97000	USD
CY2015Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	328000	USD
CY2014Q4	us-gaap	Development Stage Enterprise Deficit Accumulated During Development Stage DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage	307685000	USD
CY2015Q1	us-gaap	Development Stage Enterprise Deficit Accumulated During Development Stage DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage	312547000	USD
CY2014Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.26
CY2015Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.27
CY2014Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	1281000	USD
CY2015Q1	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	1219000	USD
CY2014Q1	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	1352000	USD
CY2015Q1	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	317000	USD
CY2015Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense After Year Five FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive	1797000	USD
CY2015Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear	210000	USD
CY2015Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Five FiniteLivedIntangibleAssetsAmortizationExpenseYearFive	280000	USD
CY2015Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	280000	USD
CY2015Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	280000	USD
CY2015Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	280000	USD
CY2015Q1	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	3127000	USD
CY2014Q1	us-gaap	Foreign Currency Transaction Gain Loss Realized ForeignCurrencyTransactionGainLossRealized	0	USD
CY2015Q1	us-gaap	Foreign Currency Transaction Gain Loss Realized ForeignCurrencyTransactionGainLossRealized	16000	USD
CY2014Q1	us-gaap	Gain Loss On Disposition Of Assets GainLossOnDispositionOfAssets	0	USD
CY2015Q1	us-gaap	Gain Loss On Disposition Of Assets GainLossOnDispositionOfAssets	35000	USD
CY2014Q1	us-gaap	Gross Profit GrossProfit	0	USD
CY2015Q1	us-gaap	Gross Profit GrossProfit	5281000	USD
CY2014Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-201000	USD
CY2015Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	460000	USD
CY2014Q1	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	-214000	USD
CY2015Q1	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	-394000	USD
CY2014Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	0	USD
CY2015Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	85000	USD
CY2014Q1	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	-17000	USD
CY2015Q1	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	-191000	USD
CY2014Q1	us-gaap	Increase Decrease In Other Operating Capital Net IncreaseDecreaseInOtherOperatingCapitalNet	0	USD
CY2015Q1	us-gaap	Increase Decrease In Other Operating Capital Net IncreaseDecreaseInOtherOperatingCapitalNet	-36000	USD
CY2014Q1	us-gaap	Increase Decrease In Receivables IncreaseDecreaseInReceivables	0	USD
CY2015Q1	us-gaap	Increase Decrease In Receivables IncreaseDecreaseInReceivables	975000	USD
CY2014Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	3197000	USD
CY2015Q1	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	3127000	USD
CY2014Q1	us-gaap	Interest Expense InterestExpense	2000	USD
CY2015Q1	us-gaap	Interest Expense InterestExpense	2000	USD
CY2014Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	384000	USD
CY2015Q1	us-gaap	Inventory Finished Goods InventoryFinishedGoods	407000	USD
CY2014Q4	us-gaap	Inventory Net InventoryNet	1920000	USD
CY2015Q1	us-gaap	Inventory Net InventoryNet	2005000	USD
CY2014Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	1078000	USD
CY2015Q1	us-gaap	Inventory Raw Materials InventoryRawMaterials	798000	USD
CY2014Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	458000	USD
CY2015Q1	us-gaap	Inventory Work In Process InventoryWorkInProcess	800000	USD
CY2014Q1	us-gaap	Investment Income Interest InvestmentIncomeInterest	4000	USD
CY2015Q1	us-gaap	Investment Income Interest InvestmentIncomeInterest	13000	USD
CY2014Q4	us-gaap	Liabilities Liabilities	11938000	USD
CY2015Q1	us-gaap	Liabilities Liabilities	12790000	USD
CY2014Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	47579000	USD
CY2015Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	44492000	USD
CY2014Q4	us-gaap	Liabilities Current LiabilitiesCurrent	11829000	USD
CY2015Q1	us-gaap	Liabilities Current LiabilitiesCurrent	12624000	USD
CY2014Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	109000	USD
CY2015Q1	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	100000	USD
CY2014Q1	us-gaap	Net Cash Provided By Used In Continuing Operations NetCashProvidedByUsedInContinuingOperations	777000	USD
CY2015Q1	us-gaap	Net Cash Provided By Used In Continuing Operations NetCashProvidedByUsedInContinuingOperations	-4440000	USD
CY2014Q1	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	5451000	USD
CY2015Q1	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	-9000	USD
CY2014Q1	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	0	USD
CY2015Q1	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-318000	USD
CY2014Q1	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-4674000	USD
CY2015Q1	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-4113000	USD
CY2014Q1	us-gaap	Net Income Loss NetIncomeLoss	-5995000	USD
CY2015Q1	us-gaap	Net Income Loss NetIncomeLoss	-4862000	USD
CY2014Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-7413000	USD
CY2015Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-6452000	USD
CY2014Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-1350000	USD
CY2015Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-290000	USD
CY2015Q1	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	1	segment
CY2014Q1	us-gaap	Operating Expenses OperatingExpenses	4645000	USD
CY2015Q1	us-gaap	Operating Expenses OperatingExpenses	9853000	USD
CY2014Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-4645000	USD
CY2015Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-4572000	USD
CY2015Q1	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	8761000	USD
CY2015Q1	us-gaap	Operating Leases Future Minimum Payments Due In Four Years OperatingLeasesFutureMinimumPaymentsDueInFourYears	253000	USD
CY2015Q1	us-gaap	Operating Leases Future Minimum Payments Due In Three Years OperatingLeasesFutureMinimumPaymentsDueInThreeYears	1350000	USD
CY2015Q1	us-gaap	Operating Leases Future Minimum Payments Due In Two Years OperatingLeasesFutureMinimumPaymentsDueInTwoYears	4047000	USD
CY2015Q1	us-gaap	Operating Leases Future Minimum Payments Due Thereafter OperatingLeasesFutureMinimumPaymentsDueThereafter	0	USD
CY2015Q1	us-gaap	Operating Leases Future Minimum Payments Remainder Of Fiscal Year OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear	3111000	USD
CY2014Q1	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	300000	USD
CY2015Q1	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	1200000	USD
CY2014Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	436000	USD
CY2015Q1	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	53000	USD
CY2014Q4	us-gaap	Other Assets Current OtherAssetsCurrent	1036000	USD
CY2015Q1	us-gaap	Other Assets Current OtherAssetsCurrent	845000	USD
CY2014Q1	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	0	USD
CY2015Q1	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-71000	USD
CY2014Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	210000	USD
CY2015Q1	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	180000	USD
CY2014Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	0	USD
CY2015Q1	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	66000	USD
CY2014Q1	us-gaap	Payments For Proceeds From Other Investing Activities PaymentsForProceedsFromOtherInvestingActivities	0	USD
CY2015Q1	us-gaap	Payments For Proceeds From Other Investing Activities PaymentsForProceedsFromOtherInvestingActivities	-35000	USD
CY2014Q1	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	0	USD
CY2015Q1	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	353000	USD
CY2015Q1	us-gaap	Share Based Compensation ShareBasedCompensation	922000	USD
CY2015Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	1188678000	USD
CY2015Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue	3448000	USD
CY2014Q1	us-gaap	Stock And Warrants Issued During Period Value Preferred Stock And Warrants StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants	145000	USD
CY2014Q1	us-gaap	Preferred Stock Accretion Of Redemption Discount PreferredStockAccretionOfRedemptionDiscount	0	USD
CY2015Q1	us-gaap	Preferred Stock Accretion Of Redemption Discount PreferredStockAccretionOfRedemptionDiscount	458000	USD
CY2014Q1	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	1418000	USD
CY2015Q1	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	1590000	USD
CY2014Q4	us-gaap	Preferred Stock Value Outstanding PreferredStockValueOutstanding	38389000	USD
CY2015Q1	us-gaap	Stock And Warrants Issued During Period Value Preferred Stock And Warrants StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants	0	USD
CY2015Q1	us-gaap	Preferred Stock Value Outstanding PreferredStockValueOutstanding	38389000	USD
CY2014Q1	us-gaap	Proceeds From Issuance Of Preferred Stock And Preference Stock ProceedsFromIssuanceOfPreferredStockAndPreferenceStock	5455000	USD
CY2015Q1	us-gaap	Proceeds From Issuance Of Preferred Stock And Preference Stock ProceedsFromIssuanceOfPreferredStockAndPreferenceStock	0	USD
CY2014Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	7289000	USD
CY2015Q1	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	8030000	USD
CY2014Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2892000	USD
CY2015Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	3446000	USD
CY2014Q1	us-gaap	Repayments Of Debt RepaymentsOfDebt	4000	USD
CY2015Q1	us-gaap	Repayments Of Debt RepaymentsOfDebt	9000	USD
CY2014Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	3271000	USD
CY2015Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	4377000	USD
CY2014	us-gaap	Restructuring Charges RestructuringCharges	3000000	USD
CY2014Q1	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	0	USD
CY2015Q1	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	10849000	USD
CY2014Q1	us-gaap	Sales Revenue Net SalesRevenueNet	0	USD
CY2015Q1	us-gaap	Sales Revenue Net SalesRevenueNet	10849000	USD
CY2014Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	1374000	USD
CY2015Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	5476000	USD
CY2014Q1	us-gaap	Share Based Compensation ShareBasedCompensation	270000	USD
CY2014Q4	us-gaap	Stockholders Equity StockholdersEquity	35641000	USD
CY2015Q1	us-gaap	Stockholders Equity StockholdersEquity	31702000	USD
CY2014Q4	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding	1081000	USD
CY2015Q1	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding	1398000	USD
CY2014Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	5868000	shares
CY2015Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	23786000	shares
CY2015Q1	us-gaap	Basis Of Accounting BasisOfAccounting	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Basis of Presentation</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div><div style="line-height:120%;text-align:justify;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The condensed consolidated financial statements included herein have been prepared in accordance with the rules and regulations of the U.S. Securities and Exchange Commission (SEC).  The preparation of condensed consolidated financial statements in conformity with generally accepted accounting principles in the United States of America (U.S. GAAP) requires management to make estimates, judgments, and assumptions that may affect the reported amounts of assets, liabilities, equity, revenues and expenses. Certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been omitted pursuant to such rules and regulations. The financial statements reflect, in the opinion of management, all adjustments (consisting only of normal, recurring adjustments) necessary to state fairly the financial position and results of operations as of and for the periods indicated.  The results of operations for the </font><font style="font-family:inherit;font-size:10pt;">three</font><font style="font-family:inherit;font-size:10pt;"> months ended </font><font style="font-family:inherit;font-size:10pt;">March 31, 2015</font><font style="font-family:inherit;font-size:10pt;">, are not necessarily indicative of the results to be expected for the full year or for any other period.  The </font><font style="font-family:inherit;font-size:10pt;">December 31, 2014</font><font style="font-family:inherit;font-size:10pt;"> condensed consolidated balance sheet data was derived from the Company’s audited consolidated financial statements, but does not include all disclosures required by U.S. GAAP.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div><div style="line-height:120%;text-align:justify;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">These condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and the notes thereto included in our Annual Report on Form 10-K for the period ended </font><font style="font-family:inherit;font-size:10pt;">December 31, 2014</font><font style="font-family:inherit;font-size:10pt;">, as filed with the SEC on March 25, 2015 (Annual Report).</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div><div style="line-height:120%;text-align:justify;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The condensed consolidated financial statements include the accounts of Vericel and its wholly-owned subsidiaries, Marrow Donation, LLC, located in San Diego, California, and Åström BIOSCIENCES DK ApS, in Kastrup, Demark (collectively, the Company).  All inter-company transactions and accounts have been eliminated in consolidation.  Aastrom Biosciences GmbH ceased operations in 2014.</font></div></div>
CY2015Q1	us-gaap	Nature Of Operations NatureOfOperations	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Organization</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div><div style="line-height:120%;text-align:justify;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Vericel Corporation a Michigan corporation, which was formerly known as Aastrom Biosciences, Inc., (the Company, Vericel, we, us or our) was incorporated in March 1989 and began employee-based operations in 1991. On May 30, 2014, Vericel completed the acquisition of certain assets and assumed certain liabilities of Sanofi, a French société anonyme (Sanofi), including all of the outstanding equity interests of Genzyme Biosurgery ApS (Genzyme Denmark or the Danish subsidiary) (now known as Åström BIOSCIENCES DK ApS), a wholly-owned subsidiary of Sanofi, and over </font><font style="font-family:inherit;font-size:10pt;">250</font><font style="font-family:inherit;font-size:10pt;"> patents and patent applications of Sanofi and certain of its subsidiaries for purposes of acquiring the portion of the cell therapy and regenerative medicine business (the CTRM Business), which researches, develops, manufactures, markets and sells the Carticel</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">®</sup></font><font style="font-family:inherit;font-size:10pt;">, MACI™, and Epicel</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">®</sup></font><font style="font-family:inherit;font-size:10pt;"> products. The Company is a fully integrated, commercial-stage biopharmaceutical company dedicated to the identification, development and commercialization of innovative therapies that enable the body to repair and regenerate damaged tissues and organs to restore normal structure and function. Vericel has marketed products as well as developmental stage product candidates and the Company’s goal is to become the leader in cell therapy and regenerative medicine by developing, manufacturing and marketing best-in-class therapies for patients with significant unmet medical needs.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div><div style="line-height:120%;text-align:justify;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company operates its business primarily in the U.S. in </font><font style="font-family:inherit;font-size:10pt;">one</font><font style="font-family:inherit;font-size:10pt;"> reportable segment — the research, product development, manufacture and distribution of patient-specific, expanded cellular therapies for use in the treatment of specific diseases.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div><div style="line-height:120%;text-align:justify;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Successful future operations are subject to several technical hurdles and risk factors, including satisfactory product development, timely initiation and completion of clinical trials, regulatory approval and market acceptance of the Company’s products, and the successful integration and profitability of the CTRM Business.</font></div></div>

Files In Submission

Name	View Source	Status
0001628280-15-004203-index-headers.html	Edgar Link	pending
0001628280-15-004203-index.html	Edgar Link	pending
0001628280-15-004203.txt	Edgar Link	pending
0001628280-15-004203-xbrl.zip	Edgar Link	pending
astm-20150331.xml	Edgar Link	completed
astm-20150331.xsd	Edgar Link	pending
astm-20150331_cal.xml	Edgar Link	unprocessable
astm-20150331_def.xml	Edgar Link	unprocessable
astm-20150331_lab.xml	Edgar Link	unprocessable
astm-20150331_pre.xml	Edgar Link	unprocessable
ex311.htm	Edgar Link	pending
ex312.htm	Edgar Link	pending
ex321.htm	Edgar Link	pending
ex322.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xls	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
vericel3311510q.htm	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$VCEL
Vericel Corp Stock $vcel

2015 Q2 Form 10-Q Financial Statement

#000162828015004203 Filed on May 14, 2015

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$VCEL Vericel Corp Stock $vcel

2015 Q2 Form 10-Q Financial Statement

#000162828015004203 Filed on May 14, 2015

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$VCEL
Vericel Corp Stock $vcel